Late Abstract Submission is now closed.

The CGC is aware of changing travel policies in our member and annual meeting participant's institutions, and has made the decision to reopen abstract submission to accommodate those members of our community who need to present their work in order to receive travel approval.

• The CGC 2025 Annual Meeting will be held on August 3-6, 2025, at the Royal Sonesta Houston Galleria, Houston, TX, USA.
• All accepted late abstracts will present posters only, as the scientific agenda is already set.
• Abstracts are selected based on scientific merit.
• The body of the abstract maximum word count has been increased in 2025 to 450 words, and abstracts should be formatted to follow the structure described below in the Abstract Submission Instructions.
• Two new abstract topics have been added in 2025, namely Pharmacogenomics and Case Studies. The Case Studies topic includes case presentations involving one or two clinical cases.
• All accepted abstracts will be published in the Cancer Genetics Journal.
• Please review CGC Continuing Medical Education (CME) Policies below for information on ineligible companies.

CGC 2025 LATE ABSTRACT TIMELINE

• CGC Membership is not required to submit an abstract. If you are not a current CGC member, simply select the option to submit "without logging in" when entering the abstract submission portal. We hope you will consider membership in the future.
• Abstracts should represent original scientific research, and the body of the abstract should be limited to a maximum of 450 words.
• Abstract submission is open for both Oncology and Constitutional topics. Suggested topics are listed below with descriptions; however, abstracts outside these topics will also be considered.
• Scientific abstracts should be structured as follows:

Introduction: Provides context and explains the problem or research question being addressed.
Methods: Outlines the study design, research procedures, and techniques used.
Results: Presents the key findings of the study in a clear and concise manner.
Discussion and Conclusion: Interprets the results, highlighting the study’s significance and implications

• Abstracts submitted in the new Case Studies category should be structured as follows:

Introduction: Emphasizes the significance or rarity of the case.
Case Presentation: Details the patient’s symptoms, history, and any relevant factors.
Diagnostic Workup and Management: Describes the diagnostic process, tests performed, and any unusual findings. In addition, discusses the care provided, including any experimental treatments.
Discussion and Conclusion: Explores the implications of the case, comparing it with existing literature or similar cases, and summarizes key insights and suggests areas for future research.

• While in the submission module, if you need to return to a previous page in the submission process, please use the back arrow on your browser.
• If the submitting author is not the presenting author, please provide the presenting author’s full name, affiliation, email address, and phone number in the designated section of the submission process.
• Submitting and presenting authors must complete a Conflict of Financial Interest Form upon submission of each abstract.
• Abstracts should avoid self-promotion and focus on rigorous, data-driven conclusions without embellishment. Case presentations should provide an overview of the symptoms, diagnosis, treatment, and follow-up of the patient, especially for unique or rare cases.
• Once an abstract is accepted, registration for the meeting will be required for participation and publication.
• Accepted abstracts will be selected for a Poster presentation only. 
• If you have challenges with your submission, please email meetings@cancergenomics.org

1. Hematologic Malignancies
2. Solid Tumors
3. Germline/Constitutional Genomics and Mosaicism (including Cancer Predisposition Risk Factors, Somatic Mosaic Disorders, etc.)
4. Automation and Other Technical Lab Topics
5. Bioinformatics, Artificial Intelligence, and Machine-Learning
6. Variant Curation, Interpretation, and Standardization
7. Emerging Technologies and other advances in Clinical Genomics (including Liquid Biopsies, cfDNA, Single-Cell, Epigenetics, Transcriptomics, Multi-Omics, etc.)
8. Pharmacogenomics (New topic in 2025)
9. Equity and Access in Genomic Medicine (including Genomic Test Implementation in Resource Limited Countries, Access to Technical Expertise, etc.)
10. Ethical and Regulatory Considerations in Genomic Testing
11. Case Studies (New topic in 2025 that includes case presentations involving one or two clinical cases)
12. Other

1. Hematologic Malignancies
Including but not limited to the discovery, development, and application of biomarkers and genomics for improving diagnosis or prognosis of acute and chronic leukemias, lymphomas, and clonal hematopoiesis (CHIP, CCUS). Topics may include diagnostic work-up and testing algorithms, practice guidelines, genomic applications in updated diagnostic classifications (e.g., WHO, ICC, NCCN), prognostication, and molecular diagnostic tools for minimal residual disease (MRD) detection. Additional areas may include targeted therapeutics such as immunotherapy, clinical correlations, risk factors, and other aspects of disease biology, including preclinical and mechanistic studies focused on novel biomarker development.

2. Solid Tumors
Including but not limited to the discovery, development, and application of biomarkers and genomics for improving the diagnosis or prognosis of solid tumors. Topics may cover diagnostic work-up and testing algorithms, practice guidelines, genomic applications in updated diagnostic criteria, prognostication, molecular diagnostic tools for minimal residual disease (MRD) detection, tumor mutational burden (TMB), and genotype-outcome correlations. Additional areas may include targeted therapeutics such as immunotherapy, clinical correlations, risk factors, and other aspects of disease biology, including preclinical and mechanistic studies focused on novel biomarker development.

3. Germline/Constitutional Genomics and Mosaicism (including Cancer Predisposition Risk Factors, Somatic Mosaic Disorders, etc.)
Including but not limited to new discoveries in diagnosis and detection approaches, genotype-phenotype correlations, clinical findings, and incidental findings of clinical significance during routine testing. Topics may also cover genetic counseling and management, polygenic risk scores, hereditary cancer syndromes, cancer predisposition, new candidate genes, vascular anomalies, tissue overgrowth syndromes, and inherited cardiomyopathies. 

4. Automation and Other Technical Lab Topics
Including but not be limited to innovations in automation within both wet and dry lab processes as they pertain to genomic assays. Topics may cover automation or technical advancements in the management and sharing of genomic-scale data, as well as the impact of automation on efficiency, accuracy, and scalability in genomic research and clinical laboratory applications.

5. Bioinformatics, Artificial Intelligence, and Machine-Learning
Including but not limited to the development, exploration, and integration of computational methodologies and machine learning algorithms for the analysis and interpretation of data to improve diagnostics and therapeutics. Topics may include novel applications in research and clinical laboratories, applications in drug interaction and development, electronic health records (EHR), integration and reporting of genomic data in EHR, challenges in bioinformatics, and computer-aided decision-making.

6. Variant Curation, Interpretation, and Standardization
Including but not limited to innovative methodologies, knowledgebase searches, computational resources, and best practices for accurately assessing genomic variants in both somatic and germline conditions. Topics may also highlight efforts in standardization for variant annotation and reporting where possible.

7. Emerging Technologies and other advances in Clinical Genomics (including Liquid Biopsies, cfDNA, Single-Cell, Epigenetics, Transcriptomics, Multi-Omics, etc.)
Including but not limited to whole genome, exome, and targeted sequencing, new library preparation kits with improved performance, optical genome mapping, long-read DNA/RNA technologies, spatial transcriptomics, methylation sequencing, liquid biopsies, cell-free DNA analysis, proteomics, cytometry by time-of-flight (cyTOF), metabolomics, and other omics. Additional topics may include novel algorithms for data analysis, laboratory automation, and applications for both research discovery and clinical laboratory implementation.

8. Pharmacogenomics (New topic in 2025)
Including but not limited to how genetics influences drug metabolizer status, with a focus in oncology. Abstracts may also address pharmacogenomics (PGx) testing in other fields, such as cardiology and neurology. Contributions on clinical PGx implementation and case studies that illustrate the impact of PGx-guided insights on optimizing treatment outcomes are also welcomed.

9. Equity and Access in Genomic Medicine (including Genomic Test Implementation in Resource Limited Countries, Access to Technical Expertise, etc.)
Including but not limited to challenges and solutions for implementing genomic testing in resource-limited settings, addressing disparities in access to genomic technologies, increasing representation in genomic databases, and enhancing access to technical expertise and training. Topics may also cover efforts to increase diversity in genomics research and strategies for improving equitable access to genomic medicine.

10. Ethical and Regulatory Considerations in Genomic Testing
Including but not limited to guidelines and regulatory compliance, economic aspects such as billing, coding, and reimbursement, resource utilization, and social and ethical considerations in genomic testing. Topics may also cover challenges in reporting, workflow optimization, data privacy, and the ethical implications of genomic testing and data sharing.

11. Case Studies (New topic in 2025)
This is a new abstract topic in 2025 that includes case presentations involving one or two clinical cases. Case presentations must describe the genetic/genomic methods used and provide relevant clinical data to support the diagnosis in question. Emphasis should be placed on the diagnostic challenge and unique insights gained from the cases. Cases submitted under this topic will be considered for a platform presentation in the new Diagnostic Challenging Cases session. Cases not selected for a platform presentation in the CGC 2025 Annual Meeting will be considered for future CGC webinars.

• Late abstracts will not be accepted as platform abstracts. Platform abstracts have already been assigned a session date and time to be orally presented. Platform presenters will be required to begin presentations with a slide disclosing any financial interest of any dollar amount or state no conflicts if none exists.
• Late abstracts accepted as a Poster are to be displayed in printed format in the exhibit hall during one of the two Poster Sessions. Poster size is three feet (3’) wide by four feet (4’) tall (portrait orientation).
• All presentations should be balanced, transparent, and supported by data.

• The abstract submission process includes an attestation that the abstract is not commercial in nature. Abstracts are expected to be fair and balanced in their presentations.
• Abstracts commercial in nature, exhibiting self-promotion, or submitted by ineligible companies will not be accepted. See new Accreditation Council for Continuing Medical Education (ACCME) definitions and information following the "Submit Abstract" button below.
• Companies who choose to support the meeting have other opportunities to present data about specific products, including the Industry Poster Session, which is only available to those companies supporting the CGC Annual Meeting. 

Cancer Genomics Consortium Continuing Medical Education (CME) Policies and Procedures

1. CGC will follow ACCME Standards for Program Development 

As a joint provider with the Mountain Area Health Education Center (MAHEC), which is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Cancer Genomics Consortium plans and produces its educational activities in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education to ensure balance, independence, objectivity and scientific rigor.  

2. Disclosure of Financial Interest 

In accordance with the ACCME Standards for Integrity and Independence, all parties (First authors of all submitted abstracts, moderators, platform presenters, program committee members, CGC board members, and CGC staff) in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ must disclose all financial relationships with any ineligible company (see ACCME definition below), for any dollar amount, within the past 24 months that creates a real or apparent conflict of interest. Individuals who do not disclose are disqualified from participating in a CME activity. 

This disclosure pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services, which are used on or directed to patients, may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be resolved prior to the educational activity. Disclosure of off-label, experimental or investigational use of drugs or devices must also be made known to the audience. 

3. Non-Participation in CME Activities by Ineligible Companies 

In August 2023, the ACCME revised their definition of a commercial interest, and renamed them as ineligible companies. By following the ACCME guidelines, the CGC will also apply this definition: 

The ACCME defines ineligible companies as "those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients." See ACCME's Standards for Integrity and Independence in Accredited Continuing Education for more information. The ACCME provides a set of self-assessment questions that can help an organization determine whether it falls under the definition of an ineligible company. These questions are listed below:

Structured Self-Assessment Related to ACCME's Definition of an Ineligible Company *

1. Does your organization, or a part of your organization, produce, market, sell, re-sell, or distribute healthcare products used by or on patients? 

2. Does your organization advocate for, or on behalf of, an ineligible company? 

3. Does your organization develop, or assist in the development of, non-accredited education in collaboration/partnership with ineligible companies? 

4. Does your organization have a parent company that 

• produces, markets, sells, re-sells, or distributes healthcare products used by or on patients, and/or 

• advocates for, or on behalf of, an ineligible company? 

• develops, or assists in the development of, non-accredited education in collaboration/partnership with ineligible companies? 

Note: A "parent company" is a separate legal entity that owns or fiscally controls an organization.

5. Does your organization have a sister company that 

• produces, markets, sells, re-sells, or distributes healthcare products used by or on patients, and/or 

• advocates for, or on behalf of, ineligible companies? 

• develops, or assists in the development of, non-accredited education in collaboration/partnership with ineligible companies? 

Note: A "sister company" is a separate legal entity which is a subsidiary of the same parent company that owns or fiscally controls an organization. 

5a. If Yes to 5, does your organization share management, employees, or governance structure with the sister company? (An example of a corporate structure that meets ACCME’s requirements for independence can be found here.) 

5b. If Yes to 5, are any owners, employees, or agents of the sister company involved in the planning, development, or implementation of educational content? 

5c. If Yes to 5, does the sister company control or influence, in whole or in part, the operations of your organization?

* If your organization answers yes to any of these questions, it would likely be defined by ACCME as an ineligible company. The CGC will follow this new ACCME regulation and cannot accept abstracts for peer review by employees of ineligible companies. Ineligible companies are encouraged to support CGC 2025 and present posters in the exhibitor poster session.

Not-for-profit or for-profit diagnostic laboratories that are not owned by device manufacturers may be considered eligible companies. Abstract submissions must have an absence of self-promotion in favor of rigorous, data-driven conclusions without embellishment. Both CGC and MAHEC will review abstracts content to ensure eligibility. All presentations must be balanced, transparent, and supported by data.